Simcere Pharmaceutical Group (SCR) Reports In-Line Q3 EPS of 7c

Simcere Pharmaceutical Group (NYSE: SCR) reported Q3 EPS of $0.07, in-line with the analyst estimate of $0.07. Revenue for the quarter came in at $83.8 million versus the consensus estimate of $85.72 million.

For earnings history and earnings-related data on Simcere Pharmaceutical Group (SCR) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Gemini Space Station, Inc. (GEMI) Misses Q2 EPS by 32c
• Eledon Pharmaceuticals, Inc. (ELDN) Misses Q2 EPS by 12c